- The first study indicates that microdosing psychedelics may enhance psychological functioning while highlighting a temporary effect, as benefits are mostly noted on dosing days with limited residual effects.
- The second study shows that participants’ expectations of microdosing benefits significantly differ from actual outcomes, emphasizing the need for more controlled investigations.
- Despite some positive changes associated with microdosing, such as reduced depression and stress, it is also linked with an increase in neuroticism, indicating that the effects are not universally beneficial.
Overview of the Study
This observational research aimed to delve into the psychological impacts of microdosing psychedelics over a six-week period. The study involved 98 participants who provided insight into their psychological functioning, revealing marked increases in reported improvements during dosing days. However, longer-term residual benefits appeared limited. The authors noted significant findings, including reductions in levels of depression and stress, enhanced absorption, and an interesting increase in neuroticism, suggesting a complex relationship between microdosing and psychological traits.
Microdosing Characteristics
Microdosing refers to the practice of consuming sub-threshold amounts of psychedelic substances, with doses often as minimal as one-twentieth of typical recreational amounts. The substances variously used include well-known psychedelics such as LSD and psilocybin. Participants commonly followed a microdosing regimen of every three days. While many proponents report various benefits, the existing empirical studies on microdosing are sparse, further motivating the current research.
Key Findings from the Initial Study
The first study revealed that microdosing often led to notable temporary inflations in psychological states, with participants experiencing enhanced mood and cognitive functions on the days they microdosed. However, these improvements were not enduring, raising questions about the long-term efficacy of microdosing as a psychological enhancement tool. Moreover, there was a consistent observation of reduced stress and depression levels. Interestingly, a corresponding rise in trait neuroticism was noted among participants, suggesting that microdosing might foster heightened emotional reactivity in some individuals.
Second Study Insights
Building on the first study, the authors conducted a follow-up investigation emphasizing participants’ expectations about microdosing outcomes. They found that individuals—whether naive or experienced in microdosing—held strong beliefs about anticipated benefits, including notable reductions in negative psychological states like depression and increased positive mental states. However, these expectations did not align with the actual changes reported in the first study. This disparity reinforces the significance of expectancy bias in shaping perceptions and experiences surrounding microdosing.
Recommendations for Future Research
Given the varied outcomes associated with microdosing, the authors conclude that more controlled and systematic studies are necessary to accurately gauge its effects and determine the safety profile of such practices. There is a clear indication that while microdosing may provide certain psychological advantages, it also introduces complexities requiring deeper exploration, specifically concerning its broader implications for mental health. Future research should focus on standardized methodologies to clarify these relationships and better inform public understanding.
Read the full paper summary on Blossom.
